{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "May 2013: 68-year-old man presented with an abnormal chest radiograph result. Further examinations revealed right upper lobe adenocarcinoma.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Radiography, Thoracic (TUI)",
              "body_part": "Thorax (TUI)",
              "modality": "X-ray",
              "finding": "abnormal",
              "date": "2013-05"
            }
          ],
          "diagnoses": [
            {
              "code": "C0242375",
              "label": "Adenocarcinoma of right upper lobe",
              "status": "active",
              "onset_date": "2013-05"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "June 2013: Underwent right upper lobectomy. Final diagnosis: stage IIA (p-T1bN1M0) lung adenocarcinoma with activating EGFR L858R mutation (detected through PNA-LNA PCR clamp method).",
        "clinical_data": {
          "procedures": [
            {
              "name": "Lobectomy",
              "approach": "open",
              "date": "2013-06",
              "location": "right upper lobe",
              "outcome": "complete resection"
            }
          ],
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung adenocarcinoma",
              "status": "historical",
              "onset_date": "2013-06"
            },
            {
              "code": "EGFR L858R mutation",
              "label": "EGFR L858R mutation",
              "status": "historical",
              "onset_date": "2013-06"
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Adjuvant chemotherapy with cisplatin and pemetrexed was started but discontinued after one course due to anorexia and hyponatremia.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0008766",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1239844",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0003123",
              "label": "Anorexia",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C0020625",
              "label": "Hyponatremia",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "August 2018: Enlarged mediastinal lymph node observed on imaging (Fig. 1A). Adenocarcinoma recurrence confirmed via biopsy with EGFR L858R mutation and PD-L1 TPS negative (<1%).",
        "clinical_data": {
          "imaging": [
            {
              "type": "Enlarged mediastinal lymph node",
              "body_part": "mediastinum",
              "modality": "imaging",
              "date": "2018-08"
            }
          ],
          "diagnoses": [
            {
              "code": "C0001637",
              "label": "Adenocarcinoma",
              "status": "active",
              "onset_date": "2018-08"
            }
          ],
          "labs": [
            {
              "test": "EGFR L858R mutation",
              "value": "positive",
              "timestamp": "2018-08"
            },
            {
              "test": "PD-L1 TPS",
              "value": "<1%",
              "flag": "negative",
              "timestamp": "2018-08"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "December 2018: Initiated first-line chemotherapy with osimertinib and ramucirumab.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1706307",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2018-12",
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C3258346",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2018-12",
              "end_date": null,
              "indication": null
            }
          ],
          "procedures": [
            {
              "name": "C0009255",
              "approach": null,
              "date": "2018-12",
              "location": null,
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "February 2019: Ramucirumab was discontinued due to adverse events of bleeding and oral mucositis; osimertinib alone was continued. Partial response achieved with osimertinib alone; no adverse events including pneumonitis experienced.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C1444734",
              "end_date": "2019-02",
              "indication": "cancer",
              "modality": "IV"
            },
            {
              "drug": "C3266593",
              "start_date": "2019-02",
              "indication": "cancer",
              "modality": "oral"
            }
          ],
          "diagnoses": [
            {
              "code": "partial response",
              "label": "Partial response",
              "status": "active"
            }
          ],
          "allergies": [
            {
              "substance": "Ramucirumab",
              "reaction": "bleeding",
              "severity": "moderate",
              "date_recorded": "2019-02"
            },
            {
              "substance": "Ramucirumab",
              "reaction": "oral mucositis",
              "severity": "moderate",
              "date_recorded": "2019-02"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Appearance of subpleural lesion after osimertinib treatment. Rebiopsy revealed squamous cell carcinoma. Reduction in the size of subpleural lesion. Mediastinal lymph nodes progressed. Rebiopsy revealed adenocarcinoma.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0007123",
              "label": "Squamous Cell Carcinoma",
              "status": "historical"
            },
            {
              "code": "C0001673",
              "label": "Adenocarcinoma",
              "status": "active"
            }
          ],
          "imaging": [
            {
              "type": "Subpleural lesion",
              "body_part": "Pleura",
              "modality": "unknown",
              "finding": "Appearance of subpleural lesion",
              "date": "unknown"
            },
            {
              "type": "Subpleural lesion",
              "body_part": "Pleura",
              "modality": "unknown",
              "finding": "Reduction in the size of subpleural lesion",
              "date": "unknown"
            },
            {
              "type": "Mediastinal lymph nodes",
              "body_part": "Mediastinum",
              "modality": "unknown",
              "finding": "Mediastinal lymph nodes progressed",
              "date": "unknown"
            }
          ],
          "medications": [
            {
              "drug": "C1697527",
              "dosage": "unknown",
              "frequency": "unknown",
              "modality": "oral",
              "start_date": "unknown",
              "end_date": "unknown",
              "indication": "unknown"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Transition from initial diagnosis to right upper lobectomy and confirmation of stage IIA lung adenocarcinoma with EGFR L858R mutation.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [
            "C0024117"
          ],
          "change_type": "other",
          "target_domain": "procedure",
          "timestamp": "2013-06"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Adjuvant chemotherapy with cisplatin and pemetrexed was initiated but discontinued after one course due to anorexia and hyponatremia.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0008766",
            "C1239844"
          ],
          "change_type": "discontinuation",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Transition from discontinued chemotherapy to observation of enlarged mediastinal lymph node and confirmation of adenocarcinoma recurrence with EGFR L858R mutation and PD-L1 TPS negative.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0024904"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis",
          "timestamp": "2018-08"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Transition from recurrence confirmation to initiation of first-line chemotherapy with osimertinib and ramucirumab.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1706307",
            "C3258346"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2018-12"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Transition from initial chemotherapy regimen to discontinuation of ramucirumab due to adverse events, continuation of osimertinib alone, and achievement of partial response.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C3258346"
          ],
          "change_type": "discontinuation",
          "target_domain": "medication",
          "timestamp": "2019-02"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Appearance of subpleural lesion after osimertinib treatment. Rebiopsy revealed squamous cell carcinoma. Reduction in the size of subpleural lesion. Mediastinal lymph nodes progressed. Rebiopsy revealed adenocarcinoma.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0206242"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    }
  ]
}